{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:24:34Z","timestamp":1787059474643,"version":"build-2736575974"},"reference-count":119,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Apparent non-response to phosphodiesterase type 5 (PDE5) inhibitors is common, but the label conflates inadequate instruction or drug exposure, partial or absent response, treatment discontinuation, and coexisting clinical contributors. This narrative review presents an author-proposed structured reassessment framework, not a new or validated diagnostic classification. Materials and Methods: PubMed\/MEDLINE was searched from database inception to 7 August 2026 using a documented, reproducible search strategy, with targeted checks of guideline, regulatory, clinical, observational, and mechanistic sources; selection was purposive, without a registered protocol, quantitative synthesis, or certainty-of-evidence grading. Results: PDE5 inhibitors preserve nitric oxide-cyclic guanosine monophosphate signaling but require sexual stimulation, adequate exposure, and sufficient erectile physiology. In one specialist-referral cohort, 88 of 250 men (35.2%) responded after structured re-education, being 88 of the 115 (76.5%) who accepted it, which should not be generalized. The framework separates trial and exposure adequacy, observed response documented with validated measures where feasible, targeted evaluation of contributing domains, and shared selection of oral optimization or an established non-oral option. Persistent clinically meaningful oral-PDE5-inhibitor non-response is defined by principle rather than by a fixed number of attempts, agents, or mandatory daily tadalafil. Conclusions: Structured reassessment may clarify why an observed response is inadequate and may support preference-sensitive management; whether it does so better than existing guidance has not been tested. Switching agents or daily tadalafil is not a prerequisite and should not delay vacuum therapy, intracavernosal injection, or penile-prosthesis discussion.<\/jats:p>","DOI":"10.3390\/medicina62081582","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:09:32Z","timestamp":1787054972000},"page":"1582","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Apparent Non-Response to Phosphodiesterase Type 5 Inhibitors in Erectile Dysfunction: A Narrative Review of Structured Reassessment and Management"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4651-312X","authenticated-orcid":false,"given":"Aris","family":"Kaltsas","sequence":"first","affiliation":[{"name":"Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/sxmrev\/qeaf035","article-title":"Evolving medical management of erectile dysfunction: Recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024)","volume":"13","author":"Stern","year":"2025","journal-title":"Sex. Med. Rev."},{"key":"ref_2","unstructured":"Salonia, A., Bettocchi, C., and Boeri, L. (2026). EAU Sexual and Reproductive Health Guidelines Panel. EAU Guidelines on Sexual and Reproductive Health, EAU Guidelines Office. Available online: https:\/\/uroweb.org\/guidelines\/sexual-and-reproductive-health."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.eururo.2025.05.004","article-title":"Erectile dysfunction: Update on clinical management","volume":"88","author":"Capogrosso","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pyrgidis, N., Mykoniatis, I., Haidich, A.B., Tirta, M., Talimtzi, P., Kalyvianakis, D., Ouranidis, A., and Hatzichristou, D. (2021). The effect of phosphodiesterase-type 5 inhibitors on erectile function: An overview of systematic reviews. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.735708"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/andr.12255","article-title":"First-generation phosphodiesterase type 5 inhibitors dropout: A comprehensive review and meta-analysis","volume":"4","author":"Corona","year":"2016","journal-title":"Andrology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5534\/wjmh.2013.31.1.31","article-title":"Treatment strategy for non-responders to PDE5 inhibitors","volume":"31","author":"Park","year":"2013","journal-title":"World J. Men\u2019s Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.urology.2014.02.016","article-title":"Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use","volume":"83","author":"Otero","year":"2014","journal-title":"Urology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.eururo.2004.12.005","article-title":"Sildenafil failures may be due to inadequate patient instructions and follow-up: A study on 100 non-responders","volume":"47","author":"Hatzichristou","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/157016106776359871","article-title":"The management of phosphodiesterase-5 (PDE5) inhibitor failure","volume":"4","author":"Lau","year":"2006","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1743-6109.2010.01772.x","article-title":"Failure of PDE5 inhibitor use: A case of nonresponder? (CME)","volume":"7","author":"Chung","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bmj.332.7541.589","article-title":"Treating erectile dysfunction when PDE5 inhibitors fail","volume":"332","author":"McMahon","year":"2006","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.5534\/wjmh.260032","article-title":"Treating Erectile Dysfunction in Phosphodiesterase 5 Inhibitors Failures\u2014Established Therapies and Newer Options","volume":"44","author":"Pescatori","year":"2026","journal-title":"World J. Men\u2019s Health"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hatzichristou, D. (2026). Beyond symptomatic treatment: PDE5 inhibitors as initiators, enablers, and sustainers of erectile function. International Journal of Impotence Research, Springer Nature.","DOI":"10.1038\/s41443-026-01329-1"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Crocetto, F., Amicuzi, U., Musone, M., Imbimbo, C., Tammaro, S., Napolitano, L., Reccia, P., De Luca, L., Del Giudice, F., and Barone, B. (2026). Erectile dysfunction: A comprehensive review of pathophysiology, diagnosis and contemporary management. Medicina, 62.","DOI":"10.3390\/medicina62050854"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1743-6109.2005.00147.x","article-title":"Women\u2019s sexual function improves when partners are administered vardenafil for erectile dysfunction: A prospective, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Goldstein","year":"2005","journal-title":"J. Sex. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/sj.ijir.3901205","article-title":"Mechanisms of action of PDE5 inhibition in erectile dysfunction","volume":"16","author":"Corbin","year":"2004","journal-title":"Int. J. Impot. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0090-4295(02)01686-2","article-title":"Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction","volume":"60","author":"Corbin","year":"2002","journal-title":"Urology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1464-410X.2005.05614.x","article-title":"Phosphodiesterase type 5 inhibitors for erectile dysfunction","volume":"96","author":"Carson","year":"2005","journal-title":"BJU Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1002\/j.1939-4640.2003.tb02744.x","article-title":"Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction","volume":"24","author":"Corbin","year":"2003","journal-title":"J. Androl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.2174\/138161209789206971","article-title":"PDE5 inhibitors: In vitro and in vivo pharmacological profile","volume":"15","author":"Kouvelas","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1111\/jsm.12335","article-title":"Nonresponders, partial responders, and complete responders to PDE5 inhibitors therapy according to IIEF criteria: Validation of an anchor-based treatment responder classification","volume":"10","author":"Yang","year":"2013","journal-title":"J. Sex. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/jsm.12130","article-title":"Adherence to initial PDE-5 inhibitor treatment: Randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction","volume":"10","author":"Buvat","year":"2013","journal-title":"J. Sex. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.euf.2021.04.019","article-title":"Digital real-world data suggest patient preference for tadalafil over sildenafil in patients with erectile dysfunction","volume":"8","author":"Rodler","year":"2022","journal-title":"Eur. Urol. Focus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: A systematic review and network meta-analysis","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00345-020-03233-9","article-title":"Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: A network meta-analysis and multicriteria decision analysis","volume":"39","author":"Madeira","year":"2021","journal-title":"World J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1464-410X.2012.11095.x","article-title":"Efficacy and safety of avanafil for treating erectile dysfunction: Results of a multicentre, randomized, double-blind, placebo-controlled trial","volume":"110","author":"Zhao","year":"2012","journal-title":"BJU Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1111\/j.1743-6109.2011.02473.x","article-title":"Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient","volume":"8","author":"Corona","year":"2011","journal-title":"J. Sex. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ogreden, E., O\u011fuz, U., Demirelli, E., Tosun, A., and Yal\u00e7\u0131n, O. (2018). Relationship between response to PDE5 inhibitors and penile duplex Doppler ultrasound in erectile dysfunction. Med. Sci., 6.","DOI":"10.20944\/preprints201801.0196.v1"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1743-6109.2009.01364.x","article-title":"Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction","volume":"6","author":"Canguven","year":"2009","journal-title":"J. Sex. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.juro.2018.05.004","article-title":"Erectile dysfunction: AUA guideline","volume":"200","author":"Burnett","year":"2018","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41443-025-01102-w","article-title":"Efficacy of vacuum erectile device in refractory erectile dysfunction: A systematic review and meta-analysis","volume":"38","author":"Zhang","year":"2026","journal-title":"Int. J. Impot. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/aja2024100","article-title":"Update on penile prosthesis","volume":"28","author":"Mykoniatis","year":"2026","journal-title":"Asian J. Androl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14740338.2016.1131818","article-title":"The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction","volume":"15","author":"Ventimiglia","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/jsxmed\/qdad163","article-title":"Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health","volume":"21","author":"Kloner","year":"2024","journal-title":"J. Sex. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.mayocp.2024.06.002","article-title":"The Princeton IV consensus recommendations for the management of erectile dysfunction and cardiovascular disease","volume":"99","author":"Kloner","year":"2024","journal-title":"Mayo Clin. Proc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jsxm.2021.06.010","article-title":"Cardiovascular outcome risks in patients with erectile dysfunction co-prescribed a phosphodiesterase type 5 inhibitor (PDE5i) and a nitrate: A retrospective observational study using electronic health record data in the United States","volume":"18","author":"Nunes","year":"2021","journal-title":"J. Sex. Med."},{"key":"ref_37","unstructured":"European Medicines Agency (2026, August 08). Cialis (Tadalafil): EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cialis-epar-product-information_en.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jsxm.2019.12.023","article-title":"Quality of clinical practice guidelines for the diagnosis and treatment of erectile dysfunction: A systematic review","volume":"17","author":"Saffon","year":"2020","journal-title":"J. Sex. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.3390\/cimb46080521","article-title":"Oxidative Stress and Erectile Dysfunction: Pathophysiology, Impacts, and Potential Treatments","volume":"46","author":"Kaltsas","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.coph.2011.08.004","article-title":"PDE5 inhibitors: Targeting erectile dysfunction in diabetics","volume":"11","author":"Francis","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zamponi, V., Mazzilli, R., Balducci, S., Faggiano, A., and Haxhi, J. (2026). Diabetic neuropathy and erectile dysfunction: Unveiling the neural pathways behind a vascular symptom. J. Clin. Med., 15.","DOI":"10.3390\/jcm15041621"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1743-6109.2005.00149.x","article-title":"Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction","volume":"2","author":"Mulhall","year":"2005","journal-title":"J. Sex. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1742-1241.2009.02328.x","article-title":"Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks","volume":"64","author":"Jackson","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.21037\/tau.2020.01.13","article-title":"Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: A systematic review and meta-analysis","volume":"9","author":"Zhu","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.21037\/tau-21-881","article-title":"Efficacy of phosphodiesterase type 5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy: A systematic review and meta-analysis","volume":"11","author":"Goh","year":"2022","journal-title":"Transl. Androl. Urol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Cabello-Garc\u00eda, M., S\u00e1nchez-Sandoval, Y., and Garc\u00eda-Rojas, A.D. (2024). Influence of personality disorders on sexual behaviours and response to treatment of psychogenic erectile dysfunction in phosphodiesterase 5 inhibitor non-responders. Front. Psychol., 15.","DOI":"10.3389\/fpsyg.2024.1496891"},{"key":"ref_47","unstructured":"Blok, B., Hamid, R., Hentzen, C., Karsenty, G., Kessler, T.M., Musco, S., Padilla-Fern\u00e1ndez, B.Y., and Panicker, J.N. (2026). EAU Guidelines on Neuro-Urology: Limited Update March 2026, EAU Guidelines Office. Available online: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Neuro-Urology-2026.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"qeag020","DOI":"10.1093\/sxmrev\/qeag020","article-title":"Internet-based cognitive behavioral therapy, web-based counseling, and online\/digital psychoeducation for male sexual dysfunction: A systematic review","volume":"14","author":"Srisadono","year":"2026","journal-title":"Sex. Med. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.14336\/AD.2019.1028","article-title":"Practical approaches to treat ED in PDE5i nonresponders","volume":"11","author":"Cai","year":"2020","journal-title":"Aging Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2013.09.037","article-title":"Tadalafil once daily in men with erectile dysfunction: An integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies","volume":"65","author":"Porst","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.urology.2017.08.031","article-title":"The efficacy of tadalafil daily vs on demand in the treatment of erectile dysfunction: A systematic review and meta-analysis","volume":"112","author":"Bansal","year":"2018","journal-title":"Urology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.esxm.2019.06.006","article-title":"Meta-analysis of the long-term efficacy and tolerance of tadalafil daily compared with tadalafil on-demand in treating men with erectile dysfunction","volume":"7","author":"Zhou","year":"2019","journal-title":"Sex. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eururo.2006.02.060","article-title":"Treatment strategy for \u201cnon-responders\u201d to tadalafil and vardenafil: A real-life study","volume":"50","author":"Hatzimouratidis","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1743-6109.04042.x","article-title":"Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil","volume":"1","author":"McMahon","year":"2004","journal-title":"J. Sex. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.juro.2010.09.035","article-title":"Onset of efficacy of tadalafil once daily in men with erectile dysfunction: A randomized, double-blind, placebo controlled trial","volume":"185","author":"Seftel","year":"2011","journal-title":"J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Hatzichristou, D., d\u2019Anzeo, G., Porst, H., Buvat, J., Henneges, C., Rossi, A., Hamidi, K., and B\u00fcttner, H. (2015). Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): Impact of patient characteristics and comorbidities. BMC Urol., 15.","DOI":"10.1186\/s12894-015-0107-5"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1464-410X.2007.07223.x","article-title":"Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection","volume":"101","author":"Kovanecz","year":"2008","journal-title":"BJU Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.eururo.2013.09.051","article-title":"Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: A randomised placebo-controlled study (REACTT)","volume":"65","author":"Montorsi","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jsxm.2016.01.022","article-title":"Effects of tadalafil once-daily or on-demand vs placebo on return to baseline erectile function after bilateral nerve-sparing radical prostatectomy\u2014Results from a randomized controlled trial (REACTT)","volume":"13","author":"Mulhall","year":"2016","journal-title":"J. Sex. Med."},{"key":"ref_60","first-page":"11350","article-title":"Recreation use of phosphodiesterase type 5 inhibitors, the other side of erectile dysfunction","volume":"95","author":"Fusco","year":"2023","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"qdag176","DOI":"10.1093\/jsxmed\/qdag176","article-title":"A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: A systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials","volume":"23","author":"Salonia","year":"2026","journal-title":"J. Sex. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/luts.12144","article-title":"Tadalafil 5 mg once daily improves lower urinary tract symptoms and erectile dysfunction: A systematic review and meta-analysis","volume":"10","author":"Wang","year":"2018","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kaltsas, A., Kratiras, Z., Zachariou, A., Dimitriadis, F., Sofikitis, N., and Chrisofos, M. (2024). Evaluating the Impact of Benign Prostatic Hyperplasia Surgical Treatments on Sexual Health. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010110"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2147\/DDDT.S124034","article-title":"Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers","volume":"11","author":"Radicioni","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Ouranidis, A., Tsiaxerli, A., Vardaka, E., Markopoulou, C.K., Zacharis, C.K., Nicolaou, I., Hatzichristou, D., Haidich, A.-B., Kostomitsopoulos, N., and Kachrimanis, K. (2021). Sildenafil 4.0\u2014Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era. Pharmaceuticals, 14.","DOI":"10.3390\/ph14040365"},{"key":"ref_66","unstructured":"IBSA Pharma Inc (2026, July 07). VYBRIQUE (Sildenafil Citrate) Oral Film: US Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/210858s000lbl.pdf."},{"key":"ref_67","unstructured":"European Medicines Agency (2026, August 08). Levitra (Vardenafil): EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/levitra-epar-product-information_en.pdf."},{"key":"ref_68","unstructured":"Aspargo Labs Italia S.r.l. (2024). Hezkue 12.5 mg\/Actuation Oromucosal Suspension: Summary of Product Characteristics, Electronic Medicines Compendium. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/101466\/smpc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0022-5347(05)65866-1","article-title":"Long-term efficacy of sildenafil and tachyphylaxis effect","volume":"166","author":"Rutland","year":"2001","journal-title":"J. Urol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1743-6109.2006.00248.x","article-title":"Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction","volume":"3","author":"McMahon","year":"2006","journal-title":"J. Sex. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4103\/2230-8210.159023","article-title":"Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Balhara","year":"2015","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00345-018-2583-1","article-title":"Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: A Bayesian network meta-analysis of randomized controlled trials","volume":"37","author":"Liao","year":"2019","journal-title":"World J. Urol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.pcd.2022.09.004","article-title":"Erectile dysfunction, phosphodiesterase-5 inhibitor use and risk of cardiovascular disease and mortality in people with diabetes: A systematic review and meta-analysis","volume":"16","author":"Seidu","year":"2022","journal-title":"Prim. Care Diabetes"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jsxm.2019.09.006","article-title":"Role of serum high-sensitivity C-reactive protein as a predictor of therapeutic response to tadalafil in patients with erectile dysfunction: A prospective observational study","volume":"16","author":"Jamaluddin","year":"2019","journal-title":"J. Sex. Med."},{"key":"ref_75","first-page":"e91566","article-title":"Predictors of dual phosphodiesterase type 5 inhibitor therapy in persons with erectile dysfunction and diabetes","volume":"17","author":"Pande","year":"2025","journal-title":"Cureus"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"qdag137","DOI":"10.1093\/jsxmed\/qdag137","article-title":"Efficacy of lifestyle interventions in treating erectile dysfunction: A systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Li","year":"2026","journal-title":"J. Sex. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1080\/14656566.2024.2422547","article-title":"Pharmacotherapeutic strategies for the management of erectile dysfunction in patients with diabetes and pre-diabetes","volume":"25","author":"Corona","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2147\/DMSO.S503216","article-title":"Effects of anti-diabetic drugs on erectile dysfunction: A systematic review and meta-analysis","volume":"18","author":"Yang","year":"2025","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/andr.70022","article-title":"Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis","volume":"13","author":"Salvio","year":"2025","journal-title":"Andrology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2025.06.010","article-title":"A holistic view of SGLT2 inhibitors: From cardio-renal management to cognitive and andrological aspects","volume":"138","author":"Cannarella","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/FJC.0000000000001624","article-title":"Erectile dysfunction risk among patients with diabetes mellitus using sodium-glucose cotransporter 2 inhibitors","volume":"84","author":"Hu","year":"2024","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1743-6109.2010.01956.x","article-title":"Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study)","volume":"8","author":"Buvat","year":"2011","journal-title":"J. Sex. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.eururo.2006.06.049","article-title":"Combining testosterone and PDE5 inhibitors in erectile dysfunction: Basic rationale and clinical evidences","volume":"50","author":"Greco","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1159\/000520135","article-title":"Testosterone therapy for late-onset hypogonadism improves erectile function: A systematic review and meta-analysis","volume":"106","author":"Taniguchi","year":"2022","journal-title":"Urol. Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1756287215576626","article-title":"Tadalafil therapy for erectile dysfunction following prostatectomy","volume":"7","author":"Brock","year":"2015","journal-title":"Ther. Adv. Urol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5353785","DOI":"10.1155\/2021\/5353785","article-title":"Cavernous nerve injury resulted erectile dysfunction and regeneration","volume":"2021","author":"Jiang","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_87","first-page":"e93901","article-title":"Low-intensity extracorporeal shock wave therapy (LI-ESWT) for erectile dysfunction in patients post-prostatectomy: A systematic review","volume":"17","author":"Singhal","year":"2025","journal-title":"Cureus"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41746-022-00670-1","article-title":"Internet- and mobile-based psychological interventions for sexual dysfunctions: A systematic review and meta-analysis","volume":"5","author":"Zarski","year":"2022","journal-title":"npj Digit. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1111\/j.1743-6109.2011.02391.x","article-title":"A randomized controlled trial of guided Internet-delivered cognitive behavioral therapy for erectile dysfunction","volume":"8","author":"Andersson","year":"2011","journal-title":"J. Sex. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/jsm.12520","article-title":"Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: A narrative review and meta-analysis","volume":"11","author":"Schmidt","year":"2014","journal-title":"J. Sex. Med."},{"key":"ref_91","unstructured":"European Medicines Agency (2026, August 11). Viagra (Sildenafil): EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/viagra-epar-product-information_en.pdf."},{"key":"ref_92","unstructured":"European Medicines Agency (2026, August 11). Spedra (Avanafil): EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/spedra-epar-product-information_en.pdf."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamaophthalmol.2022.0663","article-title":"Risk of ocular adverse events associated with use of phosphodiesterase 5 inhibitors in men in the US","volume":"140","author":"Etminan","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"qfad059","DOI":"10.1093\/sexmed\/qfad059","article-title":"Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: A Food and Drug Administration Adverse Event Reporting System analysis","volume":"11","author":"Shin","year":"2023","journal-title":"Sex. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/jsxmed\/qdac005","article-title":"Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data","volume":"20","author":"Kloner","year":"2023","journal-title":"J. Sex. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ehjcvp\/pvae029","article-title":"Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: A systematic review and meta-analysis","volume":"10","author":"Soulaidopoulos","year":"2024","journal-title":"Eur. Heart J.-Cardiovasc. Pharmacother."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Ferezin, L.P., Kayzuka, C., de Alc\u00e2ntara e Silva, M.P., Peixeiro, C.N.T., Rondon-Pereira, V.C., Tanus-Santos, J.E., and Lacchini, R. (2026). Genetic biomarkers associated with risk and therapeutic response in erectile dysfunction: A systematic review. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1771865"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Liu, Z., Wu, T., Ma, S., Xue, W., Jiang, X., Tang, Q., and Ma, J. (2022). Selecting an individualized treatment approach: The predictive value of erotic stimulation and nocturnal erections for efficacy of tadalafil and cure in patients with erectile dysfunction. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.915025"},{"key":"ref_99","unstructured":"BGP Pharma ULC (2024). VIAGRA (Sildenafil Citrate) Tablets and Orodispersible Films: Product Monograph Including Patient Medication Information, BGP Pharma ULC, a Viatris Company. Available online: https:\/\/www.viatris.ca\/en-ca\/products\/-\/media\/project\/common\/global\/pdfs\/05-08-2024-en\/20240422_viagra-pm_274068_l3_en.pdf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/and.12216","article-title":"Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction","volume":"47","author":"Cui","year":"2015","journal-title":"Andrologia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.sxmr.2018.11.007","article-title":"Systematic review of oral combination therapy for erectile dysfunction when phosphodiesterase type 5 inhibitor monotherapy fails","volume":"7","author":"Munk","year":"2019","journal-title":"Sex. Med. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e2036337","DOI":"10.1001\/jamanetworkopen.2020.36337","article-title":"Assessment of combination therapies vs monotherapy for erectile dysfunction: A systematic review and meta-analysis","volume":"4","author":"Mykoniatis","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/andr.13257","article-title":"The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors","volume":"11","author":"Tharakan","year":"2023","journal-title":"Andrology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0022-5347(05)67140-6","article-title":"Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year","volume":"164","author":"Hatzichristou","year":"2000","journal-title":"J. Urol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.juro.2015.12.049","article-title":"Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: A double-blind, sham controlled study","volume":"195","author":"Kitrey","year":"2016","journal-title":"J. Urol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"15579883221087532","DOI":"10.1177\/15579883221087532","article-title":"Systematic review and meta-analysis of 16 randomized controlled trials of clinical outcomes of low-intensity extracorporeal shock wave therapy in treating erectile dysfunction","volume":"16","author":"Yao","year":"2022","journal-title":"Am. J. Men\u2019s Health"},{"key":"ref_107","first-page":"CD013166","article-title":"Low-Intensity Shockwave Therapy for Erectile Dysfunction","volume":"2025","author":"Ergun","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jsxmed\/qdae038","article-title":"The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: A double-blind, randomized, sham-controlled clinical trial","volume":"21","author":"Kalyvianakis","year":"2024","journal-title":"J. Sex. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jsxm.2021.10.007","article-title":"The effect of combination treatment with low-intensity shockwave therapy and tadalafil on mild and mild-to-moderate erectile dysfunction: A double-blind, randomized, placebo-controlled clinical trial","volume":"19","author":"Mykoniatis","year":"2022","journal-title":"J. Sex. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/andr.70069","article-title":"Low-intensity shockwave therapy for erectile dysfunction due to diabetes mellitus or coronary artery disease: An individual participant data meta-analysis from a single center","volume":"14","author":"Pyrgidis","year":"2026","journal-title":"Andrology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2640765","DOI":"10.1080\/13685538.2026.2640765","article-title":"Current treatment for erectile dysfunction: An umbrella review of systematic reviews and meta-analyses","volume":"29","author":"Ma","year":"2026","journal-title":"Aging Male"},{"key":"ref_112","first-page":"26","article-title":"Impact of phosphodiesterase type 5 inhibitors on endothelial function","volume":"10","author":"Teloken","year":"2008","journal-title":"Rev. Urol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00345-005-0021-7","article-title":"Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors","volume":"23","author":"Sommer","year":"2005","journal-title":"World J. Urol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Bonanni, M., Rehak, L., Massaro, G., Benedetto, D., Matteucci, A., Russo, G., Esperto, F., Federici, M., Mauriello, A., and Sangiorgi, G.M. (2022). Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051091"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"qdag019","DOI":"10.1093\/jsxmed\/qdag019","article-title":"Efficacy of platelet-rich therapies versus placebo in the treatment of erectile dysfunction: An updated systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Sanches","year":"2026","journal-title":"J. Sex. Med."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Kaltsas, A., Giannakodimos, I., Markou, E., Adamos, K., Stavropoulos, M., Kratiras, Z., Zachariou, A., Dimitriadis, F., Sofikitis, N., and Chrisofos, M. (2025). The Role of Gut Microbiota Dysbiosis in Erectile Dysfunction: From Pathophysiology to Treatment Strategies. Microorganisms, 13.","DOI":"10.3390\/microorganisms13020250"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"qfag019","DOI":"10.1093\/sexmed\/qfag019","article-title":"Erectile Dysfunction and Peyronie\u2019s Disease: From Biologics to Nanomedicine-Enabled Therapies","volume":"14","author":"Kaltsas","year":"2026","journal-title":"Sex. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"qeag001","DOI":"10.1093\/sxmrev\/qeag001","article-title":"Beyond type 5 phosphodiesterase inhibitors: Potential alternative pharmacotherapy targets for erectile dysfunction","volume":"14","author":"Choudhry","year":"2026","journal-title":"Sex. Med. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/bmjebm-2025-113825","article-title":"Reporting guideline for the use of Generative Artificial intelligence tools in MEdical Research: The GAMER Statement","volume":"30","author":"Luo","year":"2025","journal-title":"BMJ Evid.-Based Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1582\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:29:17Z","timestamp":1787056157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":119,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081582"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081582","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}